Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Teva

These Are the 2 Worst-Performing S&P 500 Stocks in 2025. Should You Buy the Dip?

This article highlights the two worst-performing S&P 500 stocks in 2025 and discusses whether they present a buying opportunity.

Barchart

Can't wait for Hoka's adventure sandal to be released? Teva's new technical Grandview Max has arrived, and it's ready to tackle the trails

Teva has been crafting technical sandals for over 40 years

Advnture

Teva Pharma: Why This Generic Drug Giant Is a Smart Buy Now

Teva Pharmaceuticals is the world's largest generic drug maker with over 500 generics in its portfolio, but shares sold off on its recent earnings, buying opp?

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

2 Generic Drug Stocks Ready to Surge in 2025

Explore how Teva Pharmaceuticals and Viatris are leading the generics industry with strong growth, robust pipelines, and strategies for 2025 success.

MarketBeat

Teva Grandview GORE-TEX review: 'Triumphant' on tricky trails with supreme support and unbeatable waterproofing

The Teva Grandview GORE-TEX is an all-rounder for winter weather. Here, hiker Susan Griffin reveals why it's a must-buy this year

Woman & Home

EU Fines Teva 0M For Misusing Patent Protection

European Commission fines Teva over 460 million euros for improper practices related to Copaxone drug and disparagement of competitor.

Top News

EU Commission fines Teva $500 million for trying to stop rival's multiple sclerosis drug

The European Commission has fined Israeli generic drugmaker Teva more than 460 million euros ($500 million) for improperly seeking to protect the patent for its multiple sclerosis drug and for disparaging a rival company’s development of a competing medicine

The Independent UK

Read news from The Economist, FT, and more,
with one subscription

Post-budget sell-off of government bonds by worried City traders intensifies, pushing up UK borrowing costs – as it happened

Institute for Fiscal Studies says increasing borrowing to fund investment ‘right thing to do’

The Guardian - UK

Hoka Speedgoat 6 review: These comfortable walking shoes gave me my confidence back on the trails

If you like to walk and run for exercise, the Hoka Speedgoat 6 could be for you. Writer Susan Griffin reveals why you should give these colourful trainers a chance

Woman & Home

Ariat Skyline Summit Low Waterproof Boot review: After years of searching for my favourite walking shoe, I've gone back to basics

Hiker Susan Griffin took these Ariat walking shoes for a spin around boggy marshes and uneven trails. Here's how it went - and the winning feature that makes them her favourite

Woman & Home

We rated these Amazon walking shoes almost 5-stars in our review - and they are just £50 right now

The Jack Walker Lily Outdoor Shoes may not score top marks in the looks department but they are a winner in every other way. Here, Susan Griffin reviews

Woman & Home

Pharma company funding for patient advocacy groups needs to be transparent

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and…

The Conversation

Teva Trailwinder Low review: Finally, a comfortable pair of walking shoes I can wear every day

Teva walking shoes are some of my favourites, says hiker Susan Griffin, but the Teva Trailwinder Low takes the top spot for comfort and style - here's why.

Woman & Home

Malia Obama Brunches With a Brat Green Octopus Purse and Polarizing Sporty Sandals

The former first daughter's outfit caused quite a stir.

Marie Claire

Get all your
news in one place.

100's of premium titles.
One news app.

International Business Times

New Generic Diabetes Drug Shows How Medical Innovation Works

The drugmaker Teva Pharmaceuticals made history in June by launching the first-ever generic version of a GLP-1 diabetes drug.

Barchart

This Nike Rival is Wall Street's Next Big Stock Split, But Should You Invest?

Wall Street is eyeing a potential stock split for a Nike rival, but is this up-and-coming growth stock a good investment opportunity? Here's what investors need to know ahead of the DECK stock split.

StockNews.com

Should You Consider Buying Deckers Outdoor Corp Stock?

Deckers Outdoor’s (DECK) fourth-quarter results easily beat analysts’ expectations. While the company’s long-term outlook appears rosy with continuous innovation and a broadening product portfolio, should you invest in this stock following its earnings release? Read more to find out.

Advnture

Built for the backcountry? Teva's first-ever trail running sandal launches, designed "for an uninhibited run experience"

The brand says the Aventrail sandal delivers a lockdown fit but helps you feel further connected with nature

Get all your
news in one place.

100's of premium titles.
One news app.

Advnture

Teva and FP Movement collaborate on limited edition women’s sandals & hiking boots

Teva‘s Grandview GTX hiking boot and quick-drying Terra Fi 5 sandal get stylish makeovers

Evening Standard

Best sandals for men to wear this summer

Let us introduce you to your new season footwear rotation

Barchart

Teva Pharmaceuticals Stock Has Unusual Call Options Activity After Its Q1 Results

Teva Pharmaceuticals, the generic drug maker, posted good Q1 results today, reaffirming its forecast for significant free cash flow in 2024. That led to unusual call options activity based on a Barchart report.

StockNews.com

3 Biotech Stocks to Watch for Lucrative Gains

The biotech sector’s robust long-term growth is driven by strong government support, the rising foothold of personalized medicine, the growing number of orphan drug formulations, and rapid AI adoption. Hence, biotech stocks G1 Therapeutics (GTHX), Vanda Pharmaceuticals (VNDA), and Royalty Pharma (RPRX) could be ideal additions to your watchlist. Keep…

StockNews.com

3 Pharma Stocks Delivering Exciting April Returns

The pharmaceutical industry is expected to grow rapidly due to the ever-rising healthcare needs, increasing demand for innovative medications, and technological advancements. Therefore, fundamentally strong pharmaceutical stocks Dr. Reddy’s (RDY), Teva Pharmaceutical Industries (TEVA), and AbbVie (ABBV) could be worth adding to your portfolio. Read on.

Roll Call

Experts say Medicaid rebate change is behind inhaler price cuts - Roll Call

Three inhaler manufacturers will cap patient copays for their inhalers at $35 a month and lower the list prices of some of those products.

StockNews.com

3 Pharma Stocks to Consider for March Gains

The pharmaceutical industry is experiencing rapid growth due to rising healthcare spending, an aging population, several technological advancements, and a favorable regulatory environment. Thus, it could be ideal to invest in quality pharma stocks Perrigo (PRGO), OptiNose (OPTN), and Teva Pharmaceutical (TEVA) for solid gains. Keep reading….

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the European Commission

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.